A preliminary metabolites identification of a novel compound with β-adrenolytic activity
Open Access
- 29 May 2021
- journal article
- research article
- Published by Springer Nature in Pharmacological Reports
- Vol. 73 (5) , 1373-1389
Abstract
Background: The identification of main metabolites and assessment of renal excretion of a novel compound with β-adrenolytic activity (2RS)-1-(1H-indol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol, briefly called (RS)-9 or 2F109, were studied in vivo in rat serum, urine, faeces, liver, intestine, lungs and kidneys, and in vitro in rat liver microsomes.Methods: Structures of the metabolites have been developed by comparing the high-resolution product ion mass spectra of metabolites and the parent compound based on the differences in mass values of main fragments. Quantitative analysis of (RS)-9 was done using a system of liquid chromatography coupled with a triple quadrupole mass spectrometer API 2000. Identification studies of predicted metabolites were made by a high-resolution mass spectrometer LTQ XL Orbitrap Discovery and using a Roxy™system, for online electrochemical mimicry of oxidative metabolism by cytochrome P450s connected to QTRAP 5500.Results: For (RS)-9 (m/z357.2084) phase I metabolites derived from oxidation process: hydroxyl derivatives (m/z373.2470) and dihydroxyl derivatives (m/z389.4318), and phase II metabolites:N-methylated compound (m/z371.1612),O-glucuronide (m/z533.5118), and sulfate (m/z437.2350) were identified.Conclusion: (RS)-9 was extensively metabolised to several phase I and II metabolites, and renal excretion was a minor route in its elimination.GraphicKeywords
This publication has 27 references indexed in Scilit:
- The effects of carvedilol on cardiac structural remodeling: The role of endogenous nitric oxide in the activity of carvedilolMolecular Medicine Reports, 2013
- Enantioselective LC/ESI-MS/MS Analysis and Pharmacokinetic and Tissue Distribution Study of (2RS)-1-(7-Methoxy-1H-indol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)-propan-2-ol in RatsChirality, 2012
- Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1European Journal of Medicinal Chemistry, 2009
- High-performance liquid chromatography–tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolitesAnalytical and Bioanalytical Chemistry, 2008
- Metabolite identification by data‐dependent accurate mass spectrometric analysis at resolving power of 60 000 in external calibration mode using an LTQ/OrbitrapRapid Communications in Mass Spectrometry, 2007
- Application of liquid chromatography—Tandem mass spectrometry method for the analysis of new nonselective β‐adrenergic blocker 1‐(1‐H‐indol‐4‐yloxy)‐3‐{[2‐(2‐methoxy phenoxy)ethylo]amino}propan‐2‐ol (2F109) in rat plasmaChirality, 2007
- LC-MS-Based Metabolomics in Drug MetabolismDrug Metabolism Reviews, 2007
- Prediction of clozapine metabolism by on-line electrochemistry/liquid chromatography/mass spectrometryAnalytical and Bioanalytical Chemistry, 2005
- Comparison between electrochemistry/mass spectrometry and cytochrome P450 catalyzed oxidation reactionsRapid Communications in Mass Spectrometry, 2003
- Pharmacokinetic comparison of pindolol with other beta-adrenoceptor-blocking agentsAmerican Heart Journal, 1982